RLAY - CIK 0001812364
The table below shows Relay Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$235.46M | -$249.11M | -$300.32M | -$229.49M | -$74.41M | -$102.49M |
| Capital expenditure | $410.00K | $2.02M | $4.13M | $9.06M | $3.47M | $1.93M |
| Investing cash flow | $192.80M | -$41.08M | $257.63M | -$188.75M | -$479.51M | $81.67M |
| Dividends paid | - | - | - | - | - |
Relay Therapeutics, Inc. reported operating cash flow of -$235.46M for fiscal year 2025. That is up 5.5% from -$249.11M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$66.13M (FY 2019) to -$235.46M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $1.60M | $270.15M | $34.75M | $289.91M | $388.09M | $426.51M |